EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial

Birgit Geoerger, Lynley V Marshall, Karsten Nysom, Guy Makin, Eric Bouffet, Anne-Sophie Defachelles, Loredana Amoroso, Isabelle Aerts, Pierre Leblond, Paulette Barahona, Kim Van-Vlerken, Eric Fu und 3 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.04.007 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Birgit Geoerger und 14 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, INSERM U1015, Université Paris-Saclay, Villejuif, France. Electronic a…. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIM: This phase I/expansion study assessed the safety, pharmacokinetics and preliminary antitumor activity of afatinib in paediatric patients with cancer. METHODS: The dose-finding part enroled patients (2- 150); HER2 membrane staining (H-score>0). The primary end-points were dose-limiting toxicities (DLTs), afatinib exposure, and objective response. RESULTS: Of 564 patients pre-screened, 536 patients had biomarker data and 63 (12%) fulfilled ≥2 EGFR/HER2 criteria required for inclusion in the expansion part. A total of 56 patients were treated (17 in the dose-finding and 39 in the expansion part). DLTs were observed in one of six MTD-evaluable patients receiving 18 mg/m²/d and in two of five MTD-evaluable patients receiving 23 mg/m²/d; 18 mg/m²/d was defined as the MTD. There were no new safety signals. Pharmacokinetics confirmed exposure consistent with the approved dose in adults. One partial response (-81% per Response Assessment in Neuro-Oncology) was observed in a patient with a glioneuronal tumour harbouring a CLIP2::EGFR fusion; unconfirmed partial responses were observed in two patients. In total, 25% of patients experienced objective response or stable disease (95% confidence interval: 14-38). CONCLUSION: Targetable EGFR/HER2 drivers are rare in paediatric cancers. Treatment with afatinib led to a durable response (>3 years) in one patient with a glioneuronal tumour with CLIP2::EGFR fusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsChildHumansAfatinibAntineoplastic Combined Chemotherapy ProtocolsErbB ReceptorsChild, PreschoolAdolescent

Stichwörter der Autor:innen

AfatinibEGFREGFR::CLIP2 fusionHER2Paediatric cancer

Substanzen

AfatinibErbB Receptors

Autor:innen und Institutionen

  • Gustave Roussy Cancer Campus, Department of Pediatric and Adolescent Oncology, INSERM U1015, Université Paris-Saclay, Villejuif, France. Electronic address: birgit.geoerger@gustaveroussy.fr.
  • The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.
  • Department of Paediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Faculty of Medicine, Biology and Health, University of Manchester, Manchester, UK; Royal Manchester Children's Hospital, Manchester, UK.
  • The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
  • Centre Oscar Lambret, Lille, France.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Geoerger, B., Marshall, L. V., Nysom, K., Makin, G., Bouffet, E., Defachelles, A. S., Amoroso, L., Aerts, I., Leblond, P., Barahona, P., Van-Vlerken, K., Fu, E., Solca, F., Lorence, R. M., & Ziegler, D. S. (2023). Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.04.007

Vancouver

Geoerger B, Marshall LV, Nysom K, Makin G, Bouffet E, Defachelles AS, et al. Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.04.007

BibTeX
@article{Geoerger2023,
  author = {Geoerger, Birgit and Marshall, Lynley V and Nysom, Karsten and Makin, Guy and Bouffet, Eric and Defachelles, Anne-Sophie and Amoroso, Loredana and Aerts, Isabelle and Leblond, Pierre and Barahona, Paulette and Van-Vlerken, Kim and Fu, Eric and Solca, Flavio and Lorence, Robert M and Ziegler, David S},
  title = {Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.04.007}
}
Kostenlos starten →